Advance and stagnation in the treatment of patients with lymphoma and myeloma: Analysis using population-based cancer registry data in Japan from 1993 to 2006

International Journal of Cancer

Volumn 137, Issue 5, 2015, Pages 1217-1223

  Chihara, Dai ^a,b   Ito, Hidemi ^a   Izutsu, Koji ^c   Hattori, Masakazu ^d   Nishino, Yoshikazu ^e   Ioka, Akiko ^f   Matsuda, Tomohiro ^g   Ito, Yuri ^f  

^a AICHI CANCER CENTER HOSPITAL   (Japan)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^c TORANOMON HOSPITAL   (Japan)

^d Fukui Prefectural Hospital   (Japan)

^e MIYAGI CANCER CENTER RESEARCH INSTITUTE   (Japan)

^f OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

^g NATIONAL CANCER CENTER   (Japan)

Author keywords

cancer registry data; conditional survival; lymphoma; myeloma; relative survival

Indexed keywords

BLEOMYCIN; BORTEZOMIB; CYCLOPHOSPHAMIDE; DACARBAZINE; DEXAMETHASONE; DOXORUBICIN; LENALIDOMIDE; MELPHALAN; PREDNISONE; RITUXIMAB; THALIDOMIDE; VINBLASTINE; VINCRISTINE; ANTINEOPLASTIC AGENT;

ADOLESCENT; ADULT; AGED; AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER REGISTRY; CANCER THERAPY; CAUSE OF DEATH; DRUG APPROVAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; FOLLICULAR LYMPHOMA; HODGKIN DISEASE; HUMAN; JAPAN; LARGE CELL LYMPHOMA; LONG TERM SURVIVAL; LYMPHOMA; MAJOR CLINICAL STUDY; MALE; MULTIPLE MYELOMA; MYELOMA; PERIPHERAL T CELL LYMPHOMA; POPULATION RESEARCH; PRIORITY JOURNAL; REVIEW; SURVIVAL RATE; T CELL LEUKEMIA; T CELL LYMPHOMA; VERY ELDERLY; CLASSIFICATION; EPIDEMIOLOGY; MIDDLE AGED; MORTALITY; REGISTER; SURVIVAL; TREATMENT OUTCOME; TRENDS; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; JAPAN; LYMPHOMA; MALE; MIDDLE AGED; MULTIPLE MYELOMA; REGISTRIES; SURVIVAL ANALYSIS; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84931564436     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.29477     Document Type: Review

References (27)

1. Brenner H, Gondos A, Pulte D,. Trends in long-term survival of patients with chronic lymphocytic leukemia from the 1980s to the early 21st century. Blood 2008; 111: 4916-21.
2. Brenner H, Gondos A, Pulte D,. Recent major improvement in long-term survival of younger patients with multiple myeloma. Blood 2008; 111: 2521-6.
3. Brenner H, Gondos A, Pulte D,. Survival expectations of patients diagnosed with Hodgkin's lymphoma in 2006-2010. Oncologist 2009; 14: 806-13.
4. Pulte D, Gondos A, Brenner H,. Ongoing improvement in outcomes for patients diagnosed as having Non-Hodgkin lymphoma from the 1990s to the early 21st century. Arch Intern Med 2008; 168: 469-76.
5. Pulte D, Gondos A, Brenner H,. Trends in survival after diagnosis with hematologic malignancy in adolescence or young adulthood in the United States, 1981-2005. Cancer 2009; 115: 4973-9.
6. Pulte D, Gondos A, Brenner H,. Improvement in survival of older adults with multiple myeloma: results of an updated period analysis of SEER data. Oncologist 2011; 16: 1600-3.
7. Pulte D, Gondos A, Brenner H,. Expected long-term survival of older patients diagnosed with non-Hodgkin lymphoma in 2008-2012. Cancer Epidemiol 2012; 36: e19-25.
8. Pulte D, Jansen L, Gondos A, et al., Group improved population level survival in younger Hodgkin lymphoma patients in Germany in the early 21st century. Br J Haematol 2014; 164: 851-7.
9. Estève J, Benhamou E, Croasdale M, et al., Relative survival and the estimation of net survival: elements for further discussion. Stat Med 1990; 9: 529-38.
10. Cancer Research UK Cancer Survival Group, London School of Hygiene and Tropical Medicine. Strel computer program version 1.2.7 for cancer survival analysis. 2009.
11. Brenner H, Gefeller O,. Deriving more up-to-date estimates of long-term patient survival. J Clin Epidemiol 1997; 50: 211-6.
12. Ito Y, Miyashiro I, Ito H, et al., Long-term survival and conditional survival of cancer patients in japan using population-based cancer registry data. Cancer Sci 2014; 105: 1480-6.
13. Canellos GP, Anderson JR, Propert KJ, et al., Chemotherapy of advanced Hodgkin's disease with MOPP, ABVD, or MOPP alternating with ABVD. N Engl J Med 1992; 327: 1478-84.
14. Santoro A, Bonadonna G, Valagussa P, et al., Long-term results of combined chemotherapy-radiotherapy approach in Hodgkin's disease: superiority of ABVD plus radiotherapy versus MOPP plus radiotherapy. J Clin Oncol 1987; 5: 27-37.
15. Bonadonna G, Bonfante V, Viviani S, et al., ABVD plus subtotal nodal versus involved-field radiotherapy in early-stage Hodgkin's disease: long-term results. J Clin Oncol 2004; 22: 2835-41.
16. Schmitz N, Pfistner B, Sextro M, et al., Aggressive conventional chemotherapy compared with high-dose chemotherapy with autologous haemopoietic stem-cell transplantation for relapsed chemosensitive Hodgkin's disease: a randomised trial. Lancet 2002; 359: 2065-71.
17. Sweetenham JW, Carella AM, Taghipour G, et al., High-dose therapy and autologous stem-cell transplantation for adult patients with Hodgkin's disease who do not enter remission after induction chemotherapy: results in 175 patients reported to the European group for blood and marrow transplantation. Lymphoma working party. J Clin Oncol 1999; 17: 3101-9.
18. Hiddemann W, Kneba M, Dreyling M, et al., Frontline therapy with rituximab added to the combination of cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) significantly improves the outcome for patients with advanced-stage follicular lymphoma compared with therapy with CHOP alone: results of a prospective randomized study of the German Low-grade lymphoma study group. Blood 2005; 106: 3725-32.
19. Coiffier B, Lepage E, Briere J, et al., CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-42.
20. Chihara D, Ito H, Matsuda T, et al., Differences in incidence and trends of haematological malignancies in Japan and the United States. Br J Haematol 2014; 164: 536-45.
21. Nakamura S, Sugiyama T, Matsumoto T, et al., Long-term clinical outcome of gastric MALT lymphoma after eradication of Helicobacter pylori: a multicentre cohort follow-up study of 420 patients in Japan. Gut 2012; 61: 507-13.
22. Olszewski AJ, Castillo JJ,. Comparative outcomes of oncologic therapy in gastric extranodal marginal zone (MALT) lymphoma: analysis of the SEER-medicare database. Ann Oncol 2013; 24: 1352-9.
23. Zucca E, Conconi A, Laszlo D, et al., Addition of rituximab to chlorambucil produces superior event-free survival in the treatment of patients with extranodal marginal-zone B-cell lymphoma: 5-year analysis of the IELSG-19 randomized study. J Clin Oncol 2013; 31: 565-72.
24. McKelvey EM, Gottlieb JA, Wilson HE, et al., Hydroxyldaunomycin (adriamycin) combination chemotherapy in malignant lymphoma. Cancer 1976; 38: 1484-93.
25. d'Amore F, Relander T, Lauritzsen GF, et al., Up-front autologous stem-cell transplantation in peripheral T-cell lymphoma: NLG-T-01. J Clin Oncol 2012; 30: 3093-9.
26. Tsukasaki K, Utsunomiya A, Fukuda H, et al., VCAP-AMP-VECP compared with biweekly CHOP for adult T-cell leukemia-lymphoma: Japan clinical oncology group study JCOG9801. J Clin Oncol 2007; 25: 5458-64.
27. Rajkumar SV,. Treatment of multiple myeloma. Nat Rev Clin Oncol 2011; 8: 479-91.